PTSD Neuromodulation Targeting noninvasive VNS for PTSD presents a clear opportunity to partner with mental health clinics, VA hospitals, and research centers focused on neuromodulation therapies and post-trauma care.

Clinical Advisory Recent additions to the scientific advisory team signal credibility and potential access to hospital networks and grant opportunities; leverage introductions to clinical researchers and potential trial collaborations.

Research Tools Phoenix 100 taVNS research system positions Evren as a provider of research-grade equipment; cross-sell to neuroscience labs, universities, and contract research organizations pursuing vagus nerve stimulation studies.

Growth Stage Revenue visibility in the low to mid single digits with a lean team suggests flexibility for pilots, early adopters, and tailored pricing or bundled offerings with service/support packages to accelerate adoption.

Strategic Partnerships Board and leadership appointments indicate potential for strategic partnerships, grants, and co-development opportunities with pharmaceutical, device manufacturers, and healthcare system integrators seeking neuromodulation solutions.